Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. - Wikidata - awgldk - TriplyDB

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.

http://www.wikidata.org/entity/Q47682285

about

Current and emerging pharmacological treatments for sarcoidosis: a review Leflunomide: mode of action in the treatment of rheumatoid arthritis Lactococcus lactis dihydroorotate dehydrogenase A mutants reveal important facets of the enzymatic function Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis Protein instability and functional defects caused by mutations of dihydro-orotate dehydrogenase in Miller syndrome patients Dihydro-orotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction Leflunomide: a drug with a potential beyond rheumatology Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine Development of oral immunomodulatory agents in the management of multiple sclerosis Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.Treating rheumatoid arthritis with new disease modifying drugs.Current and emerging strategies for the management of sarcoidosis.Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds The importance of mitochondrial DNA in aging and cancer.Oral disease-modifying therapies for multiple sclerosis.Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis.Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.Asthma refractory to glucocorticoids: the role of newer immunosuppressants.Rational Design of Benzylidenehydrazinyl-Substituted Thiazole Derivatives as Potent Inhibitors of Human Dihydroorotate Dehydrogenase with in Vivo Anti-arthritic Activity.Leflunomide: long-term clinical experience and new uses.Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing.Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine.Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features.Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells.An update of teriflunomide for treatment of multiple sclerosis.Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis.Teriflunomide and its mechanism of action in multiple sclerosis.Pathophysiology of multiple sclerosis and the place of teriflunomide.Drugs in development for relapsing multiple sclerosis.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Teriflunomide: a review of its use in relapsing multiple sclerosis.Leflunomide: an immunosuppressive drug with multiple effects on T cell function.

P2860

Q24633717-D49C95CA-2093-4DBA-98E0-7F5D87280BBD Q24675005-95F9E201-5ED9-423D-B90B-689AC5B27358 Q27641154-73F58CAA-DE00-45F9-B438-ABABFAC21F5C Q28087414-4EDC15AE-824F-4A5B-997C-25E4FE0A2AF0 Q28274852-7510F24E-AA03-4F78-BBF7-D5EBBBC634BB Q28280768-B3F198AD-692A-48B4-B80F-7671D4C35C41 Q28294236-D15E48B4-08A2-41FE-9688-F9415932F3AE Q28353468-92C3AE05-03F1-48A2-A834-ED1A8F247F9D Q28388704-38BD31E5-FD09-4FD9-B656-7069C56382F1 Q28535313-33DBF42E-E3CF-4E5F-9A28-5D3D845A610D Q33869850-AB761C95-3ECF-4F96-9A81-6941BC54E1B0 Q33903812-036ECD88-0EED-433C-9BBB-DD696D07B07F Q33918869-C6BA3208-2DE8-4C40-88F3-2BA02A333B38 Q34389332-5CAA8814-08DC-4C73-B53B-54B8913036D9 Q34417518-6D371CB6-B7D9-49D9-885C-27C0BC909686 Q34567932-9FEB3689-E298-43C8-8093-D4FD01CF5F0A Q34636680-E91AC6DD-29C6-434C-8A17-E3E2CAAD55C3 Q34714866-634C65A9-419A-41F2-8233-DEACAE26B4F7 Q34760255-B2DFEE2B-B09C-4B31-91EA-730D7B1F8752 Q34974582-90FF3666-3C3C-4821-8649-6251EA242D47 Q34996562-9BF417C1-8C0F-49D9-9EC9-2E2E041CF1FB Q35092909-476270C8-705C-4B7A-B22F-83B646ECC09F Q35105760-A10FC02C-A1E6-4108-9796-BC57D4D357D5 Q35627919-6D42A40B-07B1-430E-85A4-A44E76CE77C5 Q36129211-08C4AAA1-4ADA-46DC-90B5-4FE3C95AB30D Q36150789-6E77BC29-FBBE-4F6C-BCB6-AFEEA3CE38FA Q36289418-7CE031E3-20E5-48D5-A917-F3477C4ADD5E Q36482233-ACCBDAA3-9C0E-4090-BB44-8F84D35299F9 Q36613420-B4B32190-0A28-46C9-937C-2B70C91140CD Q36618003-704057D6-B9CE-4B88-ABD1-5EB24B5D2E00 Q36733029-006902DB-EBD0-4F02-9491-A70BBCCDB2AF Q36906008-AC9125C4-C675-4DCB-A9E8-F606DB289E63 Q37358239-B1547DC7-A35F-4E05-97B2-A1948B722C4F Q37730005-288D23C8-9853-49FC-BE5E-78C4456C6DDE Q37794267-F052D78A-6801-461D-88DB-BB6DD00534A8 Q38101004-EC14A71D-B922-45A4-AF58-D7BC93D1A17A Q38107524-EA00ABE0-71E3-4AC4-9EC2-0D3E7E9EBCF9 Q38117110-53DB7A0C-806A-4B64-808C-89BD00CE9B56 Q38160410-A36017E1-FDF2-4474-A180-5E9BA80FBE7B Q38175431-6F70A05C-0081-4E29-A8B5-10700565B87E

P2860

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.

http://www.wikidata.org/entity/Q47682285

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh

1998年學術文章

@zh-hant

name

Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.

@en

Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.

@nl

type

label

Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.

@en

Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.

@nl

prefLabel

Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.

@en

Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.

@nl

P1433

Q47682285-2A82C0DB-93BE-4590-AADD-558D640730B3

P1476

Q47682285-312F357F-0D9D-4024-9F4F-822842BF241F

P2093

Q47682285-814540E8-4F95-40C6-8312-13A95ADAC652

Q47682285-8CF7261F-F26A-427B-8820-16137AA2B8B8

Q47682285-9AA3CD6A-B6B2-4EF1-8C1F-CB56DDDB5D5C

Q47682285-9DA39C7F-63B8-4917-972C-75DBBF3B22F7

Q47682285-C687C50D-D894-4141-9AB9-E59172DBBD2F

Q47682285-F96B262E-FE28-43A3-97AE-7DC6C371336B

P2860

Q47682285-30ABE9EB-E7AC-4960-BD1A-4B8053583FC8

Q47682285-343E5AA5-0AD9-44BD-B612-0E8EA57646B8

Q47682285-4A5C1996-E5B7-4A14-9775-E3FB9DA8EC8A

Q47682285-5F440058-01FA-48E3-AB33-2054D946AC6C

Q47682285-6120B5FC-0865-4F20-A339-B13E06985E90

Q47682285-68AE4764-F2C4-4879-A03C-19CFAAF75FF5

Q47682285-6C84F451-094F-4E0C-A99C-D1D872DAB526

Q47682285-6D3AC393-7296-43A2-8E4F-6DBBE9AE6784

Q47682285-7221A4B5-1B8F-432F-B5D3-D6345F986C56

Q47682285-9C45EC17-A43F-4F25-A2AE-E1459D06F5A7

P304

Q47682285-2426C02E-6323-4F0C-9B8D-93F2C9917867

P31

Q47682285-4B4F5A59-5DAA-4D49-9BED-39EB237CCFE9

P356

Q47682285-E581DDC9-87C7-4216-B388-F50BC975B51B

P407

Q47682285-2FB71F3F-C211-4F13-AA39-90C00ABAB290

P433

Q47682285-EC051A62-A09C-4CCB-8F5A-1D861D99D3E4

P478

Q47682285-F8E3FB3B-1946-442A-A21B-B0B6F8A663E0

P50

Q47682285-4664F840-6557-44E9-87DA-4566784FBE9A

P577

Q47682285-37BE7592-B5F2-4A3F-A0BE-9B005A6A6E3A

P698

Q47682285-FB0BB16C-C7B1-4843-8591-7E6FFEF4CF6C

P921

Q47682285-2DCA54CE-8EE2-409F-93B0-3541206D211D

P356

JBC.273.34.21682

P1433

Journal of Biological Chemistry

P1476

Leflunomide inhibits pyrimidin ...... mphocytes from healthy humans.

@en

P2093

Carrey EA

http://www.w3.org/2001/XMLSchema#string

Fairbanks LD

http://www.w3.org/2001/XMLSchema#string

Kirschbaum B

http://www.w3.org/2001/XMLSchema#string

Richards DF

http://www.w3.org/2001/XMLSchema#string

Rückemann K

http://www.w3.org/2001/XMLSchema#string

Simmonds HA

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.

In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine

Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.

The development of Brequinar as an immunosuppressive drug for transplantation.

Enzymes of nucleotide biosynthesis: differences between intact and lysed cells as well as between species and tissues can be important.

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.

Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme.

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.

Leflunomide interferes with pyrimidine nucleotide biosynthesis.

P304

21682-21691

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.273.34.21682

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

273

http://www.w3.org/2001/XMLSchema#string

P50

Catherine M. Hawrylowicz

P577

1998-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9705303

http://www.w3.org/2001/XMLSchema#string

P921